Loading…
Reported covered position: LD, Rep Eshoo (Jan 2013 - May 2015); Congressional Liaison - FDA (May 2015 - Feb 2018); Rep. Harman - Staff Assistant (Jun 2005 - Jun 2006); Rep. Eshoo - Leg. Correspondent, Leg. Assistant, Senior Leg. Assistant (Jan 2005 - Jan 2013).
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · first_quarter · Q1
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Education about non-opioid pain therapies and patient access to non-opioid medicines, education on alternative funding programs, education on the Million Veteran Program at the VA.
Source: Senate LDA
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
BIOSECURE Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
BIOSECURE Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
McIntire-Stennis Act District of Columbia Equality Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
McIntire-Stennis Act District of Columbia Equality Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Department of Defense Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Department of Defense Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · fourth_quarter · Q4
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · third_quarter · Q3
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · second_quarter · Q2
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · first_quarter · Q1
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · fourth_quarter · Q4
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE